Penn Medicine and IBA Form Noventra Oncology Alliance to Advance Proton Therapy Program Development
Penn Medicine and IBA have announced the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation oncology programs. The new company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation, and long-term operational performance.
The joint venture brings together the clinical, operational, research, and education expertise of Penn Medicine with IBA’s global leadership in proton therapy technology, project development, and implementation capabilities. It will provide integrated advisory and lifecycle support services to help healthcare organizations navigate the complexities of developing and sustaining successful proton therapy programs. Unlike traditional advisory models, the joint venture combines the perspectives of a leading clinical operator and the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.
As proton therapy becomes an increasingly important component of comprehensive cancer care, health systems worldwide are seeking to expand access while ensuring clinical excellence and financial sustainability. However, developing and operating a successful proton therapy program requires more than equipment acquisition. Organizations must address challenges related to strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.
James Metz, MD, Chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine, said by combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, the joint venture creates a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs.
Henri de Romrée, Deputy CEO of IBA, said a center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose. De Romrée noted that by bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. De Romrée added that the joint venture will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption.
